Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Research

Impact of an intradialysis virtual-reality-based exercise program on healthcare resources expenditure: a micro-costing analysis

Authors: Alicia García-Testal, Francisco José Martínez-Olmos, Jose Antonio Gil-Gómez, Javier Villalón-Coca, Rafael Ortiz-Ramón, Alicia Cana-Poyatos, Rafael García-Maset, Eva Segura-Ortí

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Engagement in exercise by haemodialysis (HD) patients has been shown to generate benefits both in terms of improved functional capacity and in the health-related quality of life. The use of non-immersive virtual reality (VR) games represents a new format for the implementation of intradialysis exercise. Some studies have shown that engaging in exercise for 6 months reduces the consumption of antihypertensive drugs and decreases the time spent admitted to hospital among individuals receiving HD treatments. The objective of this study was to evaluate changes in the consumption of healthcare resources and micro-costing for patients on HD who completed a VR exercise program.

Materials and methods

Design: This study is a secondary analysis of a clinical trial. The participants performed an intradialysis exercise program with non-immersive virtual reality for 3 months. The variables were recorded in two periods: 12 months before and 12 months after the start of the exercise program.

Results

The micro-costing analysis showed a significant decrease in the mean cost, in euros, for the consumption of laboratory tests − 330 (95% CI:[− 533, − 126];p = 0.003), outpatient visits − 351 ([− 566, − 135];p = 0.003), and radiology tests − 111 ([− 209, − 10];p = 0.03) in the 12 months after the implementation of the exercise program relative to the 12 months prior to its start.

Conclusion

The implementation of intradialysis exercise programs decreased the expenditure of some healthcare resources. Future studies could help clarify if longer interventions would have a stronger impact on these cost reductions.
Literature
1.
go back to reference Xu K, Soucat A, Kutzin J, Brindley C, et al. Public spending on health: a closer look at global trends. Geneva, Switzerland: World Health Organization; 2018. Xu K, Soucat A, Kutzin J, Brindley C, et al. Public spending on health: a closer look at global trends. Geneva, Switzerland: World Health Organization; 2018.
3.
go back to reference Suhrcke M, Nugent R, Stuckler D, et al. Chronic disease: an economic perspective. London: Oxford Health Alliance; 2006. Suhrcke M, Nugent R, Stuckler D, et al. Chronic disease: an economic perspective. London: Oxford Health Alliance; 2006.
6.
go back to reference Ortiz A, Covic A, Fliser D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383:1831–43.CrossRef Ortiz A, Covic A, Fliser D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383:1831–43.CrossRef
8.
go back to reference O'Hare AM1, Tawney K, Bacchetti P et al. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis. 2003;41(2):447–54. O'Hare AM1, Tawney K, Bacchetti P et al. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis. 2003;41(2):447–54.
10.
go back to reference van Oosten MJM, Logtenberg SJJ, Leegte MJH et al. Age-related difference in health care use and costs of patients with chronic kidney disease and matched controls: analysis of Dutch health care claims data. Nephrol Dial Transplant. 2019;1–9. https://doi.org/10.1093/ndt/gfz146. van Oosten MJM, Logtenberg SJJ, Leegte MJH et al. Age-related difference in health care use and costs of patients with chronic kidney disease and matched controls: analysis of Dutch health care claims data. Nephrol Dial Transplant. 2019;1–9. https://​doi.​org/​10.​1093/​ndt/​gfz146.
14.
go back to reference Segura-Orti E, Johansen KL. Exercise in end-stage renal disease. Semin Dial. 2010;23(4):422–30.CrossRef Segura-Orti E, Johansen KL. Exercise in end-stage renal disease. Semin Dial. 2010;23(4):422–30.CrossRef
15.
go back to reference Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev. 2011;10:CD003236. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev. 2011;10:CD003236.
18.
go back to reference Segura-Ortí E, Pérez-Domínguez B, Ortega‐Pérez de Villar L, et al. Virtual reality exercise intradialysis to improve physical function: A feasibility randomized trial. Scand J Med Sci Sports. 2019;29:89–94.CrossRef Segura-Ortí E, Pérez-Domínguez B, Ortega‐Pérez de Villar L, et al. Virtual reality exercise intradialysis to improve physical function: A feasibility randomized trial. Scand J Med Sci Sports. 2019;29:89–94.CrossRef
19.
25.
go back to reference Abu-Omara K, Rüttena A, Burlacua I, et al. The cost-effectiveness of physical activity interventions: a systematic review of reviews. Preventive Med Reports. 2017;8:72–8.CrossRef Abu-Omara K, Rüttena A, Burlacua I, et al. The cost-effectiveness of physical activity interventions: a systematic review of reviews. Preventive Med Reports. 2017;8:72–8.CrossRef
26.
go back to reference Parker K, Zhang X, Lewin A, et al. The association between intradialytic exercise and hospital usage among hemodialysis patients. Appl Physiol Nutr Metab. 2015;40(4):371–8.CrossRef Parker K, Zhang X, Lewin A, et al. The association between intradialytic exercise and hospital usage among hemodialysis patients. Appl Physiol Nutr Metab. 2015;40(4):371–8.CrossRef
27.
go back to reference Miller BW, Cress CL, Johnson ME, et al. Exercise during hemodialysis decreases the use of antihypertensive medications. Am J Kidney Dis. 2002;39(4):828–33.CrossRef Miller BW, Cress CL, Johnson ME, et al. Exercise during hemodialysis decreases the use of antihypertensive medications. Am J Kidney Dis. 2002;39(4):828–33.CrossRef
28.
go back to reference Wegmann G. The activity-based costing method: development and applications. IUP J Account Res Audit Practices. 2008;8(1):7–22. Wegmann G. The activity-based costing method: development and applications. IUP J Account Res Audit Practices. 2008;8(1):7–22.
29.
go back to reference Udpa S. Activity-based costing for hospitals. Health Care Manage Rev. 1996;21(3):83–96. Udpa S. Activity-based costing for hospitals. Health Care Manage Rev. 1996;21(3):83–96.
Metadata
Title
Impact of an intradialysis virtual-reality-based exercise program on healthcare resources expenditure: a micro-costing analysis
Authors
Alicia García-Testal
Francisco José Martínez-Olmos
Jose Antonio Gil-Gómez
Javier Villalón-Coca
Rafael Ortiz-Ramón
Alicia Cana-Poyatos
Rafael García-Maset
Eva Segura-Ortí
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02859-8

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.